T-Therapeutics I News
News
T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic
$32 million new equity injection adds to previously announced $59 million New investors Tencent and BGF joined by all existing major shareholders Funds will advance pipeline of novel TCR-CD3 bispecifics in cancer and autoimmune disease 13 November 2025; Cambridge, England – T-Therapeutics, a…
Read More
T-Therapeutics moves into One Granta Premises
We look forward to welcoming our staff, visitors and guests over the coming months and years at the One Granta facility. T-Therapeutics Ltd is excited to announce it has taken occupancy of the top floor of One Granta, Granta Park, Cambridge. This space…
Read More
T-Therapeutics appoints Theodora Harold as Chief Executive Officer, reflecting Company’s ambitious growth plans and progression into therapeutic development
Theodora has over 25 years’ experience in the biotech sector, with a proven track record of dynamic leadership. 10 March 2025; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble T cell receptor (TCR) therapeutics targeting cancer and autoimmune indications, announces the…
Read More
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment
Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines…
Read More
T-Therapeutics
One Granta
Granta Park
Cambridge
CB21 6DP